Translational Cancer Research
Our group has been focused for years on the identification, characterization and validation, through multidisciplinary approaches, of prognostic/predictive markers and potential therapeutic targets in tumors, in particular breast, gynecological carcinomas and sarcomas. An additional group goal is to gain insights into the molecular basis of chemo/radioresistance in cancer and to advance in the design of new, more effective and less toxic antitumor (nano)-therapies. Among our studies, we highlight those focused on analyzing the functional role in cancer of the chromosomal instability, cell cycle, mechanisms of cell death, intratumoral heterogeneity and the immune response to tumors.
Group leader
Gema Moreno Bueno
Principal Investigator
- Guillermo de Cárcer Díez
- Ricardo Sánchez Prieto
Collaborating Staff
- Ángela Montes San Lorenzo
- Carmen Ramos Nebot
- Borja Belandia Gómez
- Cristina Garnés García
- Cristina Susín Lara
- Eva Díaz Martín
- Francisco José Cimas Felipe
- Ignacio Marina Bueno
- José David Sarrió López
- José Ignacio Klett Mingo
- Lucía Pascual Antón
- María José Ruíz Hidalgo
- Saleta Morales Dolores
- Sara Lázaro Encinas
- Sara Colomo del Pino
- Sandra Ballesteros Sánchez
- Sara Oltra Sanchís
- Diego Manuel Fernández Aroca
Principal Investigator
- Guillermo de Cárcer Díez
- Ricardo Sánchez Prieto
Collaborating Staff
- Ángela Montes San Lorenzo
- Carmen Ramos Nebot
- Borja Belandia Gómez
- Cristina Garnés García
- Cristina Susín Lara
- Eva Díaz Martín
- Francisco José Cimas Felipe
- Ignacio Marina Bueno
- José David Sarrió López
- José Ignacio Klett Mingo
- Lucía Pascual Antón
- María José Ruíz Hidalgo
- Saleta Morales Dolores
- Sara Lázaro Encinas
- Sara Colomo del Pino
- Sandra Ballesteros Sánchez
- Sara Oltra Sanchís
- Diego Manuel Fernández Aroca
Strategic objectives
- Identify new mechanisms of resistance to antitumor therapy (chemotherapy, radiation therapy, immunotherapy, and targeted therapies).
- Study the molecular events related to tumor invasion and metastasis in solid tumors.
- Validate new prognostic/predictive biomarkers in cancer.
- Characterize new therapeutic approaches and/or further explore the repurposing of drugs targeting predictive biomarkers in cancer.
- Study the role of the immune system in the clinical behavior of breast and gynecological tumors.
- Elucidate the role of intratumoral heterogeneity in the clinical behavior of solid tumors.
Research lines
- Identification and characterization of novel mechanisms of resistance to antitumor therapy.
- Analysis of intratumoral heterogeneity in cancer.
- Search for new diagnostic markers in cancer.
- New therapeutic targets in cancer.
Location
Autonomous University of Madrid
Translational Cancer Research Laboratory
Department of Biochemistry, Faculty of Medicine
Sols-Morreale Biomedical Research Institute (CSIC-UAM)
Keywords
Intratumoral heterogeneity, chromosomal instability, cell cycle, cell death, resistance, targeted therapies, nanomedicine, antitumor immune response, MAPK, cell signaling, breast cancer, gynecological cancer, sarcoma